Immunoglobulin G1, Anti-(Human 5'-Nucleotidase) (Human Monoclonal Medi9447 Heavy Chain), Disulfide With Human Monoclonal Medi9447 .Lambda.-Chain, Dimer
Pancreatic Adenocarcinoma
Explore 185 assets in Pancreatic Adenocarcinoma →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04940286CT.gov Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer | — | Active Not Recruiting | — | — | — |
NCT03611556CT.gov MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Pancreatic Adenocarcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Immunoglobulin G1, Anti-(Human 5'-Nucleotidase) (Human Monoclonal Medi9447 Heavy Chain), Disulfide With Human Monoclonal Medi9447 .Lambda.-Chain, Dimer (this asset) | M.D. Anderson Cancer Center | P2 | BB · 64 |
| Fluorouracilum | Jonsson Comprehensive Cancer Center | P4 | BBB |
| Docetaxel | Bristol-Myers Squibb | P2 | BBB |
| Oxaliplatin | Jonsson Comprehensive Cancer Center | P4 | BB |
| Irinotecan | Jonsson Comprehensive Cancer Center | P3 | BB |
| Capecitabine | Zhejiang University | P4 | BB |
| Olaparib | Lantern Pharma Inc. | P3 | BB |
| Daraxonrasib | Revolution Medicines, Inc. | P3 | BB |
| Irinotecan Sucrosofate | SWOG Cancer Research Network | P3 | BB |
+42 more in the Pancreatic Adenocarcinoma cohort
Other indications for Immunoglobulin G1, Anti-(Human 5'-Nucleotidase) (Human Monoclonal Medi9447 Heavy Chain), Disulfide With Human Monoclonal Medi9447 .Lambda.-Chain, Dimer
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P3 | B · 63 |
| Colorectal Cancer | — | P2 | B · 60 |
| Castration-Resistant Prostate Carcinoma | — | P2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Immunoglobulin G1, Anti-(Human 5'-Nucleotidase) (Human Monoclonal Medi9447 Heavy Chain), Disulfide With Human Monoclonal Medi9447 .Lambda.-Chain, Dimer in Pancreatic Adenocarcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g1-anti-human-5-nucleotidase-human-monoclonal-medi9447-heavy-chain-disulfide-with-human-monoclonal-medi9447-lambda-chain-dimer-pancreatic-adenocarcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →